Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Significant Growth in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 238,617 shares, a growth of 1,545.5% from the August 31st total of 14,501 shares. Based on an average trading volume of 15,566,949 shares, the short-interest ratio is presently 0.0 days. Approximately 4.3% of the shares of the company are short sold.

Silexion Therapeutics Stock Performance

Shares of Silexion Therapeutics stock opened at $0.26 on Friday. The stock has a market capitalization of $1.45 million, a P/E ratio of -0.01 and a beta of -0.36. Silexion Therapeutics has a 52-week low of $0.24 and a 52-week high of $42.60. The stock’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $5.01.

Silexion Therapeutics (NASDAQ:SLXN) last issued its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($21.20) by $16.03. Equities research analysts forecast that Silexion Therapeutics will post -4.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on SLXN. Maxim Group cut shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Friday, September 11th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.

Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer.